These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35197258)

  • 1. Comparison of Aptamer-Based and Antibody-Based Assays for Protein Quantification in Chronic Kidney Disease.
    Lopez-Silva C; Surapaneni A; Coresh J; Reiser J; Parikh CR; Obeid W; Grams ME; Chen TK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):350-360. PubMed ID: 35197258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of Immune Activation and Incident Kidney Failure With Replacement Therapy: Findings From the African American Study of Kidney Disease and Hypertension.
    Chen TK; Estrella MM; Appel LJ; Coresh J; Luo S; Reiser J; Obeid W; Parikh CR; Grams ME
    Am J Kidney Dis; 2021 Jul; 78(1):75-84.e1. PubMed ID: 33388403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.
    Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME
    Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.
    Garlo KG; White WB; Bakris GL; Zannad F; Wilson CA; Kupfer S; Vaduganathan M; Morrow DA; Cannon CP; Charytan DM
    Clin J Am Soc Nephrol; 2018 Mar; 13(3):398-405. PubMed ID: 29339356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Metabolomic Alterations Associated with Proteinuria in CKD.
    Luo S; Coresh J; Tin A; Rebholz CM; Appel LJ; Chen J; Vasan RS; Anderson AH; Feldman HI; Kimmel PL; Waikar SS; Köttgen A; Evans AM; Levey AS; Inker LA; Sarnak MJ; Grams ME;
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):342-353. PubMed ID: 30733224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
    Weidemann DK; Abraham AG; Roem JL; Furth SL; Warady BA
    Am J Kidney Dis; 2020 Aug; 76(2):194-202. PubMed ID: 31987488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystatin C as a risk factor for outcomes in chronic kidney disease.
    Menon V; Shlipak MG; Wang X; Coresh J; Greene T; Stevens L; Kusek JW; Beck GJ; Collins AJ; Levey AS; Sarnak MJ
    Ann Intern Med; 2007 Jul; 147(1):19-27. PubMed ID: 17606957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
    Lv L; Wang F; Wu L; Wang JW; Cui Z; Hayek SS; Wei C; Reiser J; He K; Zhang L; Chen M; Zhao MH
    Nephrol Dial Transplant; 2020 Mar; 35(3):465-470. PubMed ID: 30124995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney function estimates using cystatin C versus creatinine: Impact on medication prescribing in acutely hospitalized elderly patients.
    Iversen E; Bodilsen AC; Klausen HH; Treldal C; Andersen O; Houlind MB; Petersen J
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):466-478. PubMed ID: 30372593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD.
    Bhavsar NA; Appel LJ; Kusek JW; Contreras G; Bakris G; Coresh J; Astor BC;
    Am J Kidney Dis; 2011 Dec; 58(6):886-93. PubMed ID: 21944667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
    Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
    J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC.
    Gupta J; Mitra N; Kanetsky PA; Devaney J; Wing MR; Reilly M; Shah VO; Balakrishnan VS; Guzman NJ; Girndt M; Periera BG; Feldman HI; Kusek JW; Joffe MM; Raj DS;
    Clin J Am Soc Nephrol; 2012 Dec; 7(12):1938-46. PubMed ID: 23024164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Biomarkers of Tubular Injury and Inflammation Are Associated with CKD Progression in Children.
    Greenberg JH; Abraham AG; Xu Y; Schelling JR; Feldman HI; Sabbisetti VS; Gonzalez MC; Coca S; Schrauben SJ; Waikar SS; Ramachandran VS; Shlipak MG; Warady B; Kimmel PL; Bonventre JV; Denburg M; Parikh CR; Furth S;
    J Am Soc Nephrol; 2020 May; 31(5):1067-1077. PubMed ID: 32234829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.
    Peralta CA; Shlipak MG; Judd S; Cushman M; McClellan W; Zakai NA; Safford MM; Zhang X; Muntner P; Warnock D
    JAMA; 2011 Apr; 305(15):1545-52. PubMed ID: 21482744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of the 2021 Race-Free CKD-EPI Creatinine- and Cystatin C-Based Estimated GFR Equations Among Kidney Transplant Recipients.
    Hundemer GL; White CA; Norman PA; Knoll GA; Tangri N; Sood MM; Hiremath S; Burns KD; McCudden C; Akbari A
    Am J Kidney Dis; 2022 Oct; 80(4):462-472.e1. PubMed ID: 35588905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.
    Shlipak MG; Katz R; Sarnak MJ; Fried LF; Newman AB; Stehman-Breen C; Seliger SL; Kestenbaum B; Psaty B; Tracy RP; Siscovick DS
    Ann Intern Med; 2006 Aug; 145(4):237-46. PubMed ID: 16908914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of Glomerular Filtration Rate in Elderly Chronic Kidney Disease Patients: Comparison of Three Novel Sophisticated Equations and Simple Cystatin C Equation.
    Bevc S; Hojs N; Hojs R; Ekart R; Gorenjak M; Puklavec L
    Ther Apher Dial; 2017 Apr; 21(2):126-132. PubMed ID: 28296256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Urokinase Receptor and Chronic Kidney Disease.
    Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J
    N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers During Recovery From AKI and Prediction of Long-term Reductions in Estimated GFR.
    Wilson M; Packington R; Sewell H; Bartle R; McCole E; Kurth MJ; Richardson C; Shaw S; Akani A; Banks RE; Selby NM
    Am J Kidney Dis; 2022 May; 79(5):646-656.e1. PubMed ID: 34653541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Schrauben SJ; Shou H; Zhang X; Anderson AH; Bonventre JV; Chen J; Coca S; Furth SL; Greenberg JH; Gutierrez OM; Ix JH; Lash JP; Parikh CR; Rebholz CM; Sabbisetti V; Sarnak MJ; Shlipak MG; Waikar SS; Kimmel PL; Vasan RS; Feldman HI; Schelling JR;
    J Am Soc Nephrol; 2021 Jan; 32(1):115-126. PubMed ID: 33122288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.